2 hours ago
The CLARITY Act failed to pass votes in the Senate earlier this week, a piece of legislature that would set out guardrails and ground rules for crypto **** ets in the U.S. With the failure of passage, the Securities and Exchange Commission took matters into its own hands, passing a conditional exemption Thursday for tokenized stocks. This Innovation Exemption allows for a limited type of tokenized securities to trade on specific Tokenized Securities Venues (TSVs), giving them a 5-year runway to prove their trading chops.
Tokenization is one of the latest trends in the investing world, whereby an **** et is represented digitally on a blockchain. It's seen as the next frontier in finance, with digital trading opening up greater access both for a broader investor base as well as the potential to trade 24/7, while also offering the potential for increased efficiency. However, some argue that tokenized **** ets come with added, unique risks and that by moving investments to the blockchain you introduce greater exposure to bad actors in an as-yet unregulated **** e in the U.S. That is, until now.
The SEC exemption allows for a specific type of tokenized stocks to be traded, specifically ones that retain the investor rights of the stock they are tied to (voting and dividends for example). Only tokenized U.S. National Market System (NMS) stocks qualify that trade through U.S. venues who have established standards for who can trade, limit trading volumes to a certain percentage of the stock, and make public their trading activities as well as any affiliates on the TSV. In addition, venues must halt trading when the primary exchange halts, and leverage is not permitted. Any company that does not want tokenized shares has 30 days to object and prevent their shares from being created.
It's important to note that currently there are two main types of tokenized securities, those that are directly linked to the **** et they represent digitally and those that provide synthetic exposure. Of the two, only the direct exposure tokenized stocks qualify that meet all of the exemption's restrictions.
"The Commission is not cementing today's technology as the standard for tomorrow. Instead, it is allowing the market to evolve, monitoring its development, and using that insight to inform a nimbler and future-ready regulatory framework," SEC Chair Paul Atkins said in a statement.
#exposure #commission
Tokenization is one of the latest trends in the investing world, whereby an **** et is represented digitally on a blockchain. It's seen as the next frontier in finance, with digital trading opening up greater access both for a broader investor base as well as the potential to trade 24/7, while also offering the potential for increased efficiency. However, some argue that tokenized **** ets come with added, unique risks and that by moving investments to the blockchain you introduce greater exposure to bad actors in an as-yet unregulated **** e in the U.S. That is, until now.
The SEC exemption allows for a specific type of tokenized stocks to be traded, specifically ones that retain the investor rights of the stock they are tied to (voting and dividends for example). Only tokenized U.S. National Market System (NMS) stocks qualify that trade through U.S. venues who have established standards for who can trade, limit trading volumes to a certain percentage of the stock, and make public their trading activities as well as any affiliates on the TSV. In addition, venues must halt trading when the primary exchange halts, and leverage is not permitted. Any company that does not want tokenized shares has 30 days to object and prevent their shares from being created.
It's important to note that currently there are two main types of tokenized securities, those that are directly linked to the **** et they represent digitally and those that provide synthetic exposure. Of the two, only the direct exposure tokenized stocks qualify that meet all of the exemption's restrictions.
"The Commission is not cementing today's technology as the standard for tomorrow. Instead, it is allowing the market to evolve, monitoring its development, and using that insight to inform a nimbler and future-ready regulatory framework," SEC Chair Paul Atkins said in a statement.
#exposure #commission
5 hours ago
Super Micro Computer (SMCI) stock rose 9.5% on Thursday, September 17, closing just over $40. The move followed a bullish call on how big the market for AI servers gets. That call may well be right. But it answers a question Super Micro's own results never raised. That is why one big session tells you less than it looks like it does.
Analysts at Goldman Sachs said the addressable market for AI servers will expand aggressively through the end of the decade. That is a forecast about an industry rather than about one manufacturer. Another account of Thursday morning's climb credited a broader equity rebound after Wednesday afternoon's Federal Reserve rate decision, not the forecast. Hewlett Packard Enterprise (HPE) jumped 8.0% the same day against the S&P 500's 1.1% gain, showing that capital was rotating heavily into primary AI server makers.
Company-specific headlines that day ran the other way: after the close, a shareholder rights law firm issued a press release soliciting clients for a potential investigation into company management.
A bigger market is not what this company is short of. In its fiscal fourth quarter, ended June 2026, Super Micro booked over $60 billion of new orders. That backlog underpins management's fiscal 2027 revenue guidance of $65 billion to $72 billion—up sharply from the $39 billion booked over the prior twelve months, but spread out as delivery and deployment constraints allow customers to take delivery.
What it is short of is customers ready to take delivery. Super Micro sells data center building block solutions, which bundle the servers with the power, cooling, networking and software around them. The company's manufacturing capability is on track to include more than 3,000 direct liquid-cooled racks a month.
#forecast
Analysts at Goldman Sachs said the addressable market for AI servers will expand aggressively through the end of the decade. That is a forecast about an industry rather than about one manufacturer. Another account of Thursday morning's climb credited a broader equity rebound after Wednesday afternoon's Federal Reserve rate decision, not the forecast. Hewlett Packard Enterprise (HPE) jumped 8.0% the same day against the S&P 500's 1.1% gain, showing that capital was rotating heavily into primary AI server makers.
Company-specific headlines that day ran the other way: after the close, a shareholder rights law firm issued a press release soliciting clients for a potential investigation into company management.
A bigger market is not what this company is short of. In its fiscal fourth quarter, ended June 2026, Super Micro booked over $60 billion of new orders. That backlog underpins management's fiscal 2027 revenue guidance of $65 billion to $72 billion—up sharply from the $39 billion booked over the prior twelve months, but spread out as delivery and deployment constraints allow customers to take delivery.
What it is short of is customers ready to take delivery. Super Micro sells data center building block solutions, which bundle the servers with the power, cooling, networking and software around them. The company's manufacturing capability is on track to include more than 3,000 direct liquid-cooled racks a month.
#forecast
6 hours ago
Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.
Revenue over the trailing twelve months was $66.6 billion, up 4.6% and in line with its own three-year pace. Profitability did not follow. Its operating margin over the same twelve months was 10.5%, versus a three-year average of 22.4%.
Most of that gap is one purchase. Merck took a $5.7 billion charge in the second quarter of 2026, about 9% of a year's sales. It bought Terns Pharmaceuticals, and with it MK-4208, a candidate for chronic myeloid leukemia. The bill hits earnings now and the medicine arrives later.
The proof matters because of the risk hanging over this stock. The KEYTRUDA family was just over half of Merck's revenue in the second quarter of 2026. The company is openly planning for the end of that exclusivity when Keytruda loses primary U.S. patent protection in 2028. Management describes the stretch as more of a hill than a cliff, with a shallow dip and a fast return to growth.
Johnson & Johnson (JNJ) returned 56% over the same twelve months and Pfizer (PFE) 23%, so a good year for pharmaceuticals explains some of this but not Merck's lead. What separated Merck was evidence. The FDA approved LIPFENDRA, the first and only oral PCSK9 inhibitor. In the CORALreef Lipids trial it lowered LDL cholesterol by up to 60% when added to a statin.
#year #johnson
Revenue over the trailing twelve months was $66.6 billion, up 4.6% and in line with its own three-year pace. Profitability did not follow. Its operating margin over the same twelve months was 10.5%, versus a three-year average of 22.4%.
Most of that gap is one purchase. Merck took a $5.7 billion charge in the second quarter of 2026, about 9% of a year's sales. It bought Terns Pharmaceuticals, and with it MK-4208, a candidate for chronic myeloid leukemia. The bill hits earnings now and the medicine arrives later.
The proof matters because of the risk hanging over this stock. The KEYTRUDA family was just over half of Merck's revenue in the second quarter of 2026. The company is openly planning for the end of that exclusivity when Keytruda loses primary U.S. patent protection in 2028. Management describes the stretch as more of a hill than a cliff, with a shallow dip and a fast return to growth.
Johnson & Johnson (JNJ) returned 56% over the same twelve months and Pfizer (PFE) 23%, so a good year for pharmaceuticals explains some of this but not Merck's lead. What separated Merck was evidence. The FDA approved LIPFENDRA, the first and only oral PCSK9 inhibitor. In the CORALreef Lipids trial it lowered LDL cholesterol by up to 60% when added to a statin.
#year #johnson
17 hours ago
By Nolan D. McCaskill
WASHINGTON, Sept 19 (Reuters) - Democrats are seeking to reclaim Congress, but lingering divisions from a bruising run-up to the November election threaten to imperil the party's attempt to claw back power from President Donald Trump's Republicans.
With control of both chambers at stake, Democrats have sought to move past the bad blood of the primaries, but in several competitive states, influential party figures have withheld endorsements or so far declined to campaign with nominees for the November 3 US midterm elections.
In Maine, the governor has yet to endorse the Democratic US Senate candidate. In Texas, a congresswoman has declined to campaign alongside the state representative who defeated her in the Democratic Senate primary. In Michigan, establishment centrists are steering clear of the party's progressive Senate pick. In New York, victorious democratic socialists are criticizing congressional Democrats for joining Republicans in condemning socialism. In Florida, the party has yet to rally behind its Senate nominee.
"Whether you are a progressive or an establishment Democrat or a conservative Democrat, we all have a vested interest in getting every single person over the finish line in November," said US Representative Summer Lee, a progressive Pennsylvania Democrat up for reelection.
#november #democrat #representative #declined
WASHINGTON, Sept 19 (Reuters) - Democrats are seeking to reclaim Congress, but lingering divisions from a bruising run-up to the November election threaten to imperil the party's attempt to claw back power from President Donald Trump's Republicans.
With control of both chambers at stake, Democrats have sought to move past the bad blood of the primaries, but in several competitive states, influential party figures have withheld endorsements or so far declined to campaign with nominees for the November 3 US midterm elections.
In Maine, the governor has yet to endorse the Democratic US Senate candidate. In Texas, a congresswoman has declined to campaign alongside the state representative who defeated her in the Democratic Senate primary. In Michigan, establishment centrists are steering clear of the party's progressive Senate pick. In New York, victorious democratic socialists are criticizing congressional Democrats for joining Republicans in condemning socialism. In Florida, the party has yet to rally behind its Senate nominee.
"Whether you are a progressive or an establishment Democrat or a conservative Democrat, we all have a vested interest in getting every single person over the finish line in November," said US Representative Summer Lee, a progressive Pennsylvania Democrat up for reelection.
#november #democrat #representative #declined
1 day ago
On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1.
It marked the company's third clinical setback in a week following the earlier failure of cardiovascular drug pelacarsen and a separate pause of eight trials of cell therapy rap-cel after three patient deaths. The decline erased roughly 24 billion Swiss francs, or about $29.6 billion, in market value and put Novartis on pace for one of its worst trading days in company history.
Remibrutinib provides a major remaining pipeline catalyst since Novartis AG (NYSE:NVS) reported successful late-stage results for remibrutinib in multiple sclerosis. It gives investors a credible growth driver after the failures of pelacarsen and del-desiran. The business expects more remibrutinib data later this year, making the drug an important test of whether its remaining pipeline can help long-term growth.
Novartis still expects 5% to 6% annual sales growth through 2030. Management reaffirmed its full-year financial guidance and maintained its target for 5% to 6% compound annual sales growth from 2025 through 2030. That guidance shows the company still expects its overall portfolio and remaining pipeline ******* ets to offset pressure from aging drugs.
The company retains a diversified commercial portfolio. The del-desiran failure removes a potentially important future revenue contributor, but Novartis still makes substantial revenue from its existing medicines. It also retains other pipeline ******* ets. That diversification gives the firm financial capacity to absorb individual clinical failures while it rebuilds investor confidence in its growth pipeline.
#company #remibrutinib
It marked the company's third clinical setback in a week following the earlier failure of cardiovascular drug pelacarsen and a separate pause of eight trials of cell therapy rap-cel after three patient deaths. The decline erased roughly 24 billion Swiss francs, or about $29.6 billion, in market value and put Novartis on pace for one of its worst trading days in company history.
Remibrutinib provides a major remaining pipeline catalyst since Novartis AG (NYSE:NVS) reported successful late-stage results for remibrutinib in multiple sclerosis. It gives investors a credible growth driver after the failures of pelacarsen and del-desiran. The business expects more remibrutinib data later this year, making the drug an important test of whether its remaining pipeline can help long-term growth.
Novartis still expects 5% to 6% annual sales growth through 2030. Management reaffirmed its full-year financial guidance and maintained its target for 5% to 6% compound annual sales growth from 2025 through 2030. That guidance shows the company still expects its overall portfolio and remaining pipeline ******* ets to offset pressure from aging drugs.
The company retains a diversified commercial portfolio. The del-desiran failure removes a potentially important future revenue contributor, but Novartis still makes substantial revenue from its existing medicines. It also retains other pipeline ******* ets. That diversification gives the firm financial capacity to absorb individual clinical failures while it rebuilds investor confidence in its growth pipeline.
#company #remibrutinib
1 day ago
Data center developer Crusoe said Thursday it raised $3.9 billion in a Series F round that pushes its valuation to $30.9 billion. The massive round was co-led by Atreides Management, Mubadala Capital, and Valor Equity Partners. Founders Fund, GIC, Nvidia, Qatar Investment Authority (QIA), Radical Ventures, and TPG also participated, according to Crusoe.
Crusoe also announced three new board members, including Cloudflare CFO Thomas Seifert; Bill Stein, partner and CIO at Primary Digital Infrastructure; and Redwood Materials founder and CEO JB Straubel, who also sits on Tesla's board. Straubel already has ties to Crusoe; he personally invested in the company in 2021, and Crusoe later became the first customer of Redwood's energy storage business.
The eight-year-old company's fresh capital infusion will help finance existing data center projects, including a large site in Abilene, Texas, used by OpenAI, as well as smaller, modular AI factories that can be transported by truck and connected to large power sources almost anywhere.
By manufacturing these modular data centers, called Spark, at its own facilities, Crusoe can deploy compute capacity quickly and without the need for large construction workforces. The smaller centers could also help Crusoe sidestep, at least in part, another major obstacle facing data center developers: backlash from local communities protesting massive complexes near their neighborhoods.
Crusoe co-founder and CEO Chase Lochmiller, who is pictured above, said in a statement he believes AI will usher in an era of abundance, but to get there will mean "controlling the infrastructure from electrons to tokens, and we're grateful to have investors who share that conviction."
#straubel #round
Crusoe also announced three new board members, including Cloudflare CFO Thomas Seifert; Bill Stein, partner and CIO at Primary Digital Infrastructure; and Redwood Materials founder and CEO JB Straubel, who also sits on Tesla's board. Straubel already has ties to Crusoe; he personally invested in the company in 2021, and Crusoe later became the first customer of Redwood's energy storage business.
The eight-year-old company's fresh capital infusion will help finance existing data center projects, including a large site in Abilene, Texas, used by OpenAI, as well as smaller, modular AI factories that can be transported by truck and connected to large power sources almost anywhere.
By manufacturing these modular data centers, called Spark, at its own facilities, Crusoe can deploy compute capacity quickly and without the need for large construction workforces. The smaller centers could also help Crusoe sidestep, at least in part, another major obstacle facing data center developers: backlash from local communities protesting massive complexes near their neighborhoods.
Crusoe co-founder and CEO Chase Lochmiller, who is pictured above, said in a statement he believes AI will usher in an era of abundance, but to get there will mean "controlling the infrastructure from electrons to tokens, and we're grateful to have investors who share that conviction."
#straubel #round
1 day ago
In late 2022, OpenAI released ChatGPT, and within months the bottom rung of the tech-industry career ladder started to disappear. Graduates who majored in computer science and other AI-exposed fields are increasingly missing out on the jobs they trained for, and a chunk of them are landing behind restaurant counters and retail registers instead, according to two Census Bureau papers.
An April 2026 Census paper tracked matched employer-employee records and found that hiring of workers ages 22 to 24 fell sharply in the industries most exposed to AI, while hiring in less-exposed industries held steady. Employment for early-career workers in the most AI-exposed fifth of industries dropped 12% over the ten quarters after ChatGPT's release. Lee Tucker, one of the coauthors of the paper, said "the decline in hires is the primary cause" of that rate of unemployment, not people losing jobs they already had.
That mattered most for one type of graduate. The most AI-exposed industries, Tucker found, cluster heavily around software and information-technology work, which are the very fields computer science and other highly AI-exposed majors are built to feed into.
A second paper from last week, also coauthored by Tucker, follows the graduates of the most AI-exposed decile of college majors. Their odds of holding a job one quarter after graduation fell by five percentage points, and full-quarter initial earnings dropped 13% following ChatGPT's release. A 13% earnings decline is roughly the size economists would expect from graduating into a severe recession—except there wasn't one, since the rest of the labor market held up fine.
Young grads still need to work and still have jobs, even if they've received highly exposed degrees. So the decline in earnings is less about a lack of employment and more about pursuing lower-wage occupations to make ends meet.
#graduates
An April 2026 Census paper tracked matched employer-employee records and found that hiring of workers ages 22 to 24 fell sharply in the industries most exposed to AI, while hiring in less-exposed industries held steady. Employment for early-career workers in the most AI-exposed fifth of industries dropped 12% over the ten quarters after ChatGPT's release. Lee Tucker, one of the coauthors of the paper, said "the decline in hires is the primary cause" of that rate of unemployment, not people losing jobs they already had.
That mattered most for one type of graduate. The most AI-exposed industries, Tucker found, cluster heavily around software and information-technology work, which are the very fields computer science and other highly AI-exposed majors are built to feed into.
A second paper from last week, also coauthored by Tucker, follows the graduates of the most AI-exposed decile of college majors. Their odds of holding a job one quarter after graduation fell by five percentage points, and full-quarter initial earnings dropped 13% following ChatGPT's release. A 13% earnings decline is roughly the size economists would expect from graduating into a severe recession—except there wasn't one, since the rest of the labor market held up fine.
Young grads still need to work and still have jobs, even if they've received highly exposed degrees. So the decline in earnings is less about a lack of employment and more about pursuing lower-wage occupations to make ends meet.
#graduates
2 days ago
Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-severe atopic dermatitis. The primary measure was the percentage change from baseline in Eczema Area and Severity Index, or EASI, at week 12. No tested dose met the primary or secondary endpoints, and development in that indication will stop.
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p
2 days ago
Even before we go deeper, I want to be upfront about this. I think Dario Amodei's concerns about the pace of artificial intelligence (AI) development deserve to be taken seriously.
As the CEO of Anthropic, one of the companies building this technology, he has a front-row view of where AI is heading. That alone gives his warnings a perspective most of us don't have.
Dario Amodei published an essay **** led "We Must Pace the Frontier" on Sep. 12, 2026, calling for an intentional slowdown in advanced AI development.
He received remarkable support. OpenAI CEO Sam Altman endorsed it. Elon Musk said Amodei was "right." Even competitors in a fiercely competitive industry agreed that independent evaluators made sense.
This has been a primary topic of discussion for some time. I also think that if AI development continues at its current pace without safeguards, there is a real risk that we could eventually confront the darker side of what the technology is capable of doing.
Yes, of course, the potential benefits are enormous, but so are the consequences if its risks outpace our ability to manage them.
#pace #dario #anthropic #must
As the CEO of Anthropic, one of the companies building this technology, he has a front-row view of where AI is heading. That alone gives his warnings a perspective most of us don't have.
Dario Amodei published an essay **** led "We Must Pace the Frontier" on Sep. 12, 2026, calling for an intentional slowdown in advanced AI development.
He received remarkable support. OpenAI CEO Sam Altman endorsed it. Elon Musk said Amodei was "right." Even competitors in a fiercely competitive industry agreed that independent evaluators made sense.
This has been a primary topic of discussion for some time. I also think that if AI development continues at its current pace without safeguards, there is a real risk that we could eventually confront the darker side of what the technology is capable of doing.
Yes, of course, the potential benefits are enormous, but so are the consequences if its risks outpace our ability to manage them.
#pace #dario #anthropic #must
2 days ago
With a market cap of $16.7 billion, NVR, Inc. (NVR) is a leading company operating through two primary business segments: homebuilding and mortgage banking. Its homebuilding segment constructs and sells homes under the Ryan Homes, NVHomes, and Heartland Homes brands.
Companies valued at $10 billion or more are generally considered "large-cap" stocks, and NVR fits this criterion perfectly. The company serves customers across 37 metropolitan areas in 16 states and Washington, D.C.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
The Case for Selling CrowdStrike Stock
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
#Companies
Companies valued at $10 billion or more are generally considered "large-cap" stocks, and NVR fits this criterion perfectly. The company serves customers across 37 metropolitan areas in 16 states and Washington, D.C.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
The Case for Selling CrowdStrike Stock
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
#Companies
3 days ago
Rep. Thomas Massie (R-Ky.) argued Wednesday that House GOP leaders sent the lower chamber home early because they found other Republicans in support of his push to impeach Defense Secretary Pete Hegseth.
“The fact that they didn’t vote on it tells me that they did a whip check, and they probably found that there were some other Republicans, besides me, that were going to vote for this, or at least didn’t want to be on the record supporting Hegseth,” he told host Kaitlan Collins on CNN’s “The Source.”
The outgoing Kentucky libertarian, a frequent critic of President Trump, introduced eight articles of impeachment against Hegseth on Tuesday.
Massie accused Hegseth of violating his “oath to support and defend the Constitution of the United States,” citing his handling of the Iran war and operations to kill alleged drug traffickers in the Caribbean Sea and eastern Pacific Ocean.
The GOP lawmaker, who lost his primary in May to Trump-backed Ed Gallrein, also made his impeachment resolution privileged.
#hegseth #Trump #found #didn
“The fact that they didn’t vote on it tells me that they did a whip check, and they probably found that there were some other Republicans, besides me, that were going to vote for this, or at least didn’t want to be on the record supporting Hegseth,” he told host Kaitlan Collins on CNN’s “The Source.”
The outgoing Kentucky libertarian, a frequent critic of President Trump, introduced eight articles of impeachment against Hegseth on Tuesday.
Massie accused Hegseth of violating his “oath to support and defend the Constitution of the United States,” citing his handling of the Iran war and operations to kill alleged drug traffickers in the Caribbean Sea and eastern Pacific Ocean.
The GOP lawmaker, who lost his primary in May to Trump-backed Ed Gallrein, also made his impeachment resolution privileged.
#hegseth #Trump #found #didn
3 days ago
Answering a caller's query about The Procter & Gamble Company (NYSE:PG) during the lightning round of the September 10 episode of Mad Money, Jim Cramer said:
It's a tough stock. It's a tough stock because they don't have the growth that I want. They do have the 3% yield, but that's not enough. So, I'm going to say, you know, we sold it for the club. Don't look back.
The Procter & Gamble Company's (NYSE:PG) upside relies on elite operational execution and pricing power in high-margin categories. Continuous supply chain savings and an aggressive premiumization push toward items like Tide PODS help protect profitability. Combined with strong free cash flow productivity, management returned roughly $15 billion in FY 2026 through dividends and share buybacks, ensuring a steady earnings floor despite slow top-line growth.
The primary headwind is weak top-line momentum, with organic sales flat in the second quarter as challenging consumer trends, particularly in the U.S., weighed on growth. Foreign exchange friction and cost pressures further cap near-term earnings acceleration. Additionally, while the stock offers a reliable 3% dividend yield, that income profile creates a steep opportunity cost when risk-free ******* ets and higher-growth stocks offer attractive returns. We recently discussed what Cramer thinks is the ideal valuation for a good entry point in our article, "Jim Cramer Discusses Procter & Gamble (PG) Valuation and Growth."
According to Insider Monkey's data, 83 hedge funds had a stake in The Procter & Gamble Company (NYSE:PG) in Q2 compared to 78 in the prior quarter. Short percentage of the float is 1.21%, showing its status as a defensive holding rather than a short target. While the company provides exceptional balance sheet stability and reliable cash returns for defensive portfolios, its modest top-line growth trajectory and premium valuation continue to test investor patience, validating Cramer's decision to reallocate capital toward faster-moving opportunities.
#company
It's a tough stock. It's a tough stock because they don't have the growth that I want. They do have the 3% yield, but that's not enough. So, I'm going to say, you know, we sold it for the club. Don't look back.
The Procter & Gamble Company's (NYSE:PG) upside relies on elite operational execution and pricing power in high-margin categories. Continuous supply chain savings and an aggressive premiumization push toward items like Tide PODS help protect profitability. Combined with strong free cash flow productivity, management returned roughly $15 billion in FY 2026 through dividends and share buybacks, ensuring a steady earnings floor despite slow top-line growth.
The primary headwind is weak top-line momentum, with organic sales flat in the second quarter as challenging consumer trends, particularly in the U.S., weighed on growth. Foreign exchange friction and cost pressures further cap near-term earnings acceleration. Additionally, while the stock offers a reliable 3% dividend yield, that income profile creates a steep opportunity cost when risk-free ******* ets and higher-growth stocks offer attractive returns. We recently discussed what Cramer thinks is the ideal valuation for a good entry point in our article, "Jim Cramer Discusses Procter & Gamble (PG) Valuation and Growth."
According to Insider Monkey's data, 83 hedge funds had a stake in The Procter & Gamble Company (NYSE:PG) in Q2 compared to 78 in the prior quarter. Short percentage of the float is 1.21%, showing its status as a defensive holding rather than a short target. While the company provides exceptional balance sheet stability and reliable cash returns for defensive portfolios, its modest top-line growth trajectory and premium valuation continue to test investor patience, validating Cramer's decision to reallocate capital toward faster-moving opportunities.
#company
3 days ago
On September 10, a caller outlined a detailed financial thesis showing Micron Technology, Inc. (NASDAQ:MU) reaching $1,400 and asked whether the **** ysis held water. In response, Mad Money host Jim Cramer said:
I mean, that's a remarkable **** ysis. It's spot on in every single number. Every single thing you said is true, which is why my Charitable Trust owns it, and why we are buying it aggressively. And by the way, can I just say if you listen to what… [the caller] said, he put some money away. He was fortunate enough to have money, which I know not everybody can have, but he had money. He put it in an individual stock. Now, if he put it in an index fund, he'd make some money, but he got really rich. And part of my job is not just to get you rich, but to hopefully get you really rich.
Micron Technology, Inc. (NASDAQ:MU) stands as one of three primary global manufacturers of dynamic random-access memory (DRAM) and NAND flash memory, positioning it at the center of the ongoing expansion in artificial intelligence infrastructure. Because advanced AI workloads require significantly higher memory bandwidth, demand has surged for Micron's High-Bandwidth Memory (HBM3E) architecture, which is integrated directly into top-tier AI graphics processors and data center accelerators. With memory production capacity for advanced AI chips remaining constrained industry-wide, Micron has secured long-term purchase agreements that cover its HBM output through 2026 and into 2027, providing visibility into top-line revenue growth.
Driven by accelerated AI server adoption and broader pricing recovery across traditional DRAM and NAND markets, it reported extraordinary growth in fiscal Q3. Revenue surged to $41.46 billion, more than quadrupling the $9.30 billion generated in the same period last year and stepping up sharply from $23.86 billion in the prior quarter. The company demonstrated exceptional operating leverage during the period, posting GAAP net income of $28.24 billion ($24.67 per diluted share) and non-GAAP net income of $28.86 billion ($25.11 per diluted share). Operating cash flow also scaled quickly, reaching $25.39 billion compared to $11.90 billion in the prior quarter and $4.61 billion in the prior-year period.
Despite its strong position in the AI supply chain, Micron Technology, Inc. (NASDAQ:MU) operates in a historically cyclical memory industry with some operational and market risks. Memory chip pricing remains sensitive to industry-wide supply-and-demand imbalances, where oversupply can rapidly compress profit margins during broader downturns in consumer electronics demand or corporate IT spending.
#billion #memory #NASDAQ #industry
I mean, that's a remarkable **** ysis. It's spot on in every single number. Every single thing you said is true, which is why my Charitable Trust owns it, and why we are buying it aggressively. And by the way, can I just say if you listen to what… [the caller] said, he put some money away. He was fortunate enough to have money, which I know not everybody can have, but he had money. He put it in an individual stock. Now, if he put it in an index fund, he'd make some money, but he got really rich. And part of my job is not just to get you rich, but to hopefully get you really rich.
Micron Technology, Inc. (NASDAQ:MU) stands as one of three primary global manufacturers of dynamic random-access memory (DRAM) and NAND flash memory, positioning it at the center of the ongoing expansion in artificial intelligence infrastructure. Because advanced AI workloads require significantly higher memory bandwidth, demand has surged for Micron's High-Bandwidth Memory (HBM3E) architecture, which is integrated directly into top-tier AI graphics processors and data center accelerators. With memory production capacity for advanced AI chips remaining constrained industry-wide, Micron has secured long-term purchase agreements that cover its HBM output through 2026 and into 2027, providing visibility into top-line revenue growth.
Driven by accelerated AI server adoption and broader pricing recovery across traditional DRAM and NAND markets, it reported extraordinary growth in fiscal Q3. Revenue surged to $41.46 billion, more than quadrupling the $9.30 billion generated in the same period last year and stepping up sharply from $23.86 billion in the prior quarter. The company demonstrated exceptional operating leverage during the period, posting GAAP net income of $28.24 billion ($24.67 per diluted share) and non-GAAP net income of $28.86 billion ($25.11 per diluted share). Operating cash flow also scaled quickly, reaching $25.39 billion compared to $11.90 billion in the prior quarter and $4.61 billion in the prior-year period.
Despite its strong position in the AI supply chain, Micron Technology, Inc. (NASDAQ:MU) operates in a historically cyclical memory industry with some operational and market risks. Memory chip pricing remains sensitive to industry-wide supply-and-demand imbalances, where oversupply can rapidly compress profit margins during broader downturns in consumer electronics demand or corporate IT spending.
#billion #memory #NASDAQ #industry
3 days ago
On September 10, Imperial Petroleum Inc. (NASDAQ:IMPP), a company involved in seaborne transportation of crude oil, dry bulk, and petroleum products, released its second quarter results. With a topline figure of $87.1 million, the company delivered record quarterly revenue, which also resulted in 139.9% year-over-year growth. Imperial's adjusted EBITDA for the second quarter stood at $41.7 million, while the Q2 adjusted net income of $35.3 million exhibited around 163% growth in comparison with Q2 FY25.
Ralf Gosch/Shutterstock.com
Several factors contributed to the second quarter topline growth. A 6.9 vessel rise in the company's average fleet size was the primary growth enabler. Other factors include encouraging dynamics across the drybulk segment, and higher rates for both drybulk and tankers amid the geopolitical uncertainties. Operating income for the quarter jumped to a near-record level of $33.4 million, which translates into a 307.3% growth relative to Q2 FY25. Imperial posted an adjusted EPS of $0.76 for the reported quarter, which almost doubled compared to the same quarter a year prior.
At the back of efficient fleet management, management remained focus on strengthening its financial position. The company ended the quarter with no debt, and its liquidity position also remained resilient. Cash and cash equivalents, including time deposits, increased from $179.1 million at the end of 2025 to $245.2 million as of June 30, 2026. The company added that its cash base had increased further to approximately $260 million as of the September 10 results release.
Certain areas of weakness warrant a closer examination. During the reported quarter, fleet operational utilization went down from 83.1% in prior year's second quarter to 73.5%. There was a substantial increase in some of the underlying operating expenses. For instance, the vessel operating expense stood at $14.4 million compared to $8.4 million during Q2 FY25. This $6 million rise can be attributed to Imperial's larger fleet size. Similarly, the voyage expenses also jumped from $10.7 million in last year's Q2 to $22.1 million for Q2 FY26. The incremental voyage expenses stemmed from higher bunkers' rates, as well as a 58.4% jump in spot days.
#fleet
Ralf Gosch/Shutterstock.com
Several factors contributed to the second quarter topline growth. A 6.9 vessel rise in the company's average fleet size was the primary growth enabler. Other factors include encouraging dynamics across the drybulk segment, and higher rates for both drybulk and tankers amid the geopolitical uncertainties. Operating income for the quarter jumped to a near-record level of $33.4 million, which translates into a 307.3% growth relative to Q2 FY25. Imperial posted an adjusted EPS of $0.76 for the reported quarter, which almost doubled compared to the same quarter a year prior.
At the back of efficient fleet management, management remained focus on strengthening its financial position. The company ended the quarter with no debt, and its liquidity position also remained resilient. Cash and cash equivalents, including time deposits, increased from $179.1 million at the end of 2025 to $245.2 million as of June 30, 2026. The company added that its cash base had increased further to approximately $260 million as of the September 10 results release.
Certain areas of weakness warrant a closer examination. During the reported quarter, fleet operational utilization went down from 83.1% in prior year's second quarter to 73.5%. There was a substantial increase in some of the underlying operating expenses. For instance, the vessel operating expense stood at $14.4 million compared to $8.4 million during Q2 FY25. This $6 million rise can be attributed to Imperial's larger fleet size. Similarly, the voyage expenses also jumped from $10.7 million in last year's Q2 to $22.1 million for Q2 FY26. The incremental voyage expenses stemmed from higher bunkers' rates, as well as a 58.4% jump in spot days.
#fleet
3 days ago
Our ****** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Delivered total revenue growth of 1.1%, marking the second consecutive quarter of expansion as the Project Sunshine transformation gains traction.
Direct segment revenue grew 8% with comparable sales up 9.2%, serving as the primary indicator of customer resonance with new product and marketing strategies.
Gross margin expanded by more than 40 basis points (excluding tariff refunds) through disciplined pricing, promotion governance, and improved product ****** ortment productivity.
Indirect channel revenue contracted 39% due to intentional shifts in marketplace strategy and a strategic reduction in liquidation sales to protect brand equity.
#tell
Delivered total revenue growth of 1.1%, marking the second consecutive quarter of expansion as the Project Sunshine transformation gains traction.
Direct segment revenue grew 8% with comparable sales up 9.2%, serving as the primary indicator of customer resonance with new product and marketing strategies.
Gross margin expanded by more than 40 basis points (excluding tariff refunds) through disciplined pricing, promotion governance, and improved product ****** ortment productivity.
Indirect channel revenue contracted 39% due to intentional shifts in marketplace strategy and a strategic reduction in liquidation sales to protect brand equity.
#tell
3 days ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#vaccine #pfizer #NYSE
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#vaccine #pfizer #NYSE
3 days ago
With Agentic AI accelerating CPU server chip demand, Wall Street believes Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the primary beneficiaries taking share. On September 9, Piper Sandler ******* yst David O'Connor initiated coverage on AMD (NASDAQ: AMD) with an Overweight rating and a $600 price target.
Analyst O'Connor estimates revenue for FY26-30 to grow at a 50% CAGR, while earnings per share compound at 65%.
The server-CPU share gain story for AMD is simple, Agentic AI is expected to increase demand for server CPUs. This is because the workloads require continuous control-plane activity, API calls, database queries and tool execution. AMD will benefit from this use based on its high-frequency and general-purpose processors with its Venice portfolio.
Even AMD executives have highlighted that AMD is now transitioning from merely a semiconductor supplier to a provider of rack-scale systems and software. It is also positioning its server CPU portfolio for increased demand from agentic AI workloads.
The company reported second-quarter revenue of $11.5 billion, beating ******* yst estimates. This includes $6.7 billion from data centers, up 107% year-over-year. The segment performance was attributed to EPYC processors and Instinct GPUs.
#workloads
Analyst O'Connor estimates revenue for FY26-30 to grow at a 50% CAGR, while earnings per share compound at 65%.
The server-CPU share gain story for AMD is simple, Agentic AI is expected to increase demand for server CPUs. This is because the workloads require continuous control-plane activity, API calls, database queries and tool execution. AMD will benefit from this use based on its high-frequency and general-purpose processors with its Venice portfolio.
Even AMD executives have highlighted that AMD is now transitioning from merely a semiconductor supplier to a provider of rack-scale systems and software. It is also positioning its server CPU portfolio for increased demand from agentic AI workloads.
The company reported second-quarter revenue of $11.5 billion, beating ******* yst estimates. This includes $6.7 billion from data centers, up 107% year-over-year. The segment performance was attributed to EPYC processors and Instinct GPUs.
#workloads
3 days ago
Our ****** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Launched ReefIQ in June as a proprietary substrate layer designed to convert unstructured biological data into structured representations for pharmaceutical AI models.
Transitioned the commercial strategy from discrete fee-for-service projects to broader platform partnerships where MindWalk participates in the long-term economics of created ****** ets.
Achieved a significant infrastructure milestone by validating OpenFold3 on AMD Instinct MI325X GPUs, enhancing discovery scale and ReefIQ's biological context layer.
Leveraged a deep wet-lab discovery franchise, including relationships with 19 of the top 20 global pharma companies, as a primary distribution channel for new AI platform adoption.
#june
Launched ReefIQ in June as a proprietary substrate layer designed to convert unstructured biological data into structured representations for pharmaceutical AI models.
Transitioned the commercial strategy from discrete fee-for-service projects to broader platform partnerships where MindWalk participates in the long-term economics of created ****** ets.
Achieved a significant infrastructure milestone by validating OpenFold3 on AMD Instinct MI325X GPUs, enhancing discovery scale and ReefIQ's biological context layer.
Leveraged a deep wet-lab discovery franchise, including relationships with 19 of the top 20 global pharma companies, as a primary distribution channel for new AI platform adoption.
#june
3 days ago
Our ****** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Saleable coal production grew 8% to 11.5 million tonnes, exceeding guidance due to the successful ramp-up of New Acland and Bengalla returning to nameplate capacity.
Management attributed the 10% decline in average realized price to $145 per tonne to broader market cyclicality, though low-cost ****** ets maintained a resilient $45 per tonne margin.
Bengalla's performance was impacted by a temporary increase in strip ratio and pit resequencing following significant weather events late in the 2025 financial year.
The group shifted its primary safety metric to High Potential Event Frequency Rate (HPEFR) to focus on preventing fatal or life-altering risks rather than just traditional injury counts.
#tell #Event
Saleable coal production grew 8% to 11.5 million tonnes, exceeding guidance due to the successful ramp-up of New Acland and Bengalla returning to nameplate capacity.
Management attributed the 10% decline in average realized price to $145 per tonne to broader market cyclicality, though low-cost ****** ets maintained a resilient $45 per tonne margin.
Bengalla's performance was impacted by a temporary increase in strip ratio and pit resequencing following significant weather events late in the 2025 financial year.
The group shifted its primary safety metric to High Potential Event Frequency Rate (HPEFR) to focus on preventing fatal or life-altering risks rather than just traditional injury counts.
#tell #Event
3 days ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
3 days ago
Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Saleable coal production grew 8% to 11.5 million tonnes, exceeding guidance due to the successful ramp-up of New Acland and Bengalla returning to nameplate capacity.
Management attributed the 10% decline in average realized price to $145 per tonne to broader market cyclicality, though low-cost **** ets maintained a resilient $45 per tonne margin.
Bengalla's performance was impacted by a temporary increase in strip ratio and pit resequencing following significant weather events late in the 2025 financial year.
The group shifted its primary safety metric to High Potential Event Frequency Rate (HPEFR) to focus on preventing fatal or life-altering risks rather than just traditional injury counts.
#tonne #saleable #acland
Saleable coal production grew 8% to 11.5 million tonnes, exceeding guidance due to the successful ramp-up of New Acland and Bengalla returning to nameplate capacity.
Management attributed the 10% decline in average realized price to $145 per tonne to broader market cyclicality, though low-cost **** ets maintained a resilient $45 per tonne margin.
Bengalla's performance was impacted by a temporary increase in strip ratio and pit resequencing following significant weather events late in the 2025 financial year.
The group shifted its primary safety metric to High Potential Event Frequency Rate (HPEFR) to focus on preventing fatal or life-altering risks rather than just traditional injury counts.
#tonne #saleable #acland
3 days ago
Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Launched ReefIQ in June as a proprietary substrate layer designed to convert unstructured biological data into structured representations for pharmaceutical AI models.
Transitioned the commercial strategy from discrete fee-for-service projects to broader platform partnerships where MindWalk participates in the long-term economics of created **** ets.
Achieved a significant infrastructure milestone by validating OpenFold3 on AMD Instinct MI325X GPUs, enhancing discovery scale and ReefIQ's biological context layer.
Leveraged a deep wet-lab discovery franchise, including relationships with 19 of the top 20 global pharma companies, as a primary distribution channel for new AI platform adoption.
#reefiq
Launched ReefIQ in June as a proprietary substrate layer designed to convert unstructured biological data into structured representations for pharmaceutical AI models.
Transitioned the commercial strategy from discrete fee-for-service projects to broader platform partnerships where MindWalk participates in the long-term economics of created **** ets.
Achieved a significant infrastructure milestone by validating OpenFold3 on AMD Instinct MI325X GPUs, enhancing discovery scale and ReefIQ's biological context layer.
Leveraged a deep wet-lab discovery franchise, including relationships with 19 of the top 20 global pharma companies, as a primary distribution channel for new AI platform adoption.
#reefiq
4 days ago
WASHINGTON (AP) — The United States has confirmed for the first time that it has deployed weapons in ******* e, a remarkable revelation after previous warnings about countries such as Russia possibly weaponizing a global frontier long agreed in treaties to be used for only peaceful purposes.
Air Force Secretary Troy Meink said Monday that the U.S. has fielded "on-orbit ******* e control weapons capable of defending the Joint Force against hostile adversary action."
Meink did not detail what the weapons were, how they work or if they were targeting other objects in ******* e or on Earth. The U.S. had warned two years ago that Russia was developing a new ******* e-based, anti-satellite weapon, though the White House said the danger wasn't imminent at the time.
But reports of the anti-satellite weapon reflected longstanding worries about ******* e threats from Russia and China, given that much U.S. infrastructure is dependent on satellite communications. The U.S. has also previously demonstrated its own abilities to shoot down satellites from Earth.
In his remarks to the Air and ******* e Forces ******* ociation's Air, ******* e & Cyber Conference, Meink also said the Air Force was adding more autonomous systems to its capabilities and predicted the service would look "radically different" by 2032. For example, he foresaw one-way attack drones replacing artillery as the "primary killer."
#space #earth
Air Force Secretary Troy Meink said Monday that the U.S. has fielded "on-orbit ******* e control weapons capable of defending the Joint Force against hostile adversary action."
Meink did not detail what the weapons were, how they work or if they were targeting other objects in ******* e or on Earth. The U.S. had warned two years ago that Russia was developing a new ******* e-based, anti-satellite weapon, though the White House said the danger wasn't imminent at the time.
But reports of the anti-satellite weapon reflected longstanding worries about ******* e threats from Russia and China, given that much U.S. infrastructure is dependent on satellite communications. The U.S. has also previously demonstrated its own abilities to shoot down satellites from Earth.
In his remarks to the Air and ******* e Forces ******* ociation's Air, ******* e & Cyber Conference, Meink also said the Air Force was adding more autonomous systems to its capabilities and predicted the service would look "radically different" by 2032. For example, he foresaw one-way attack drones replacing artillery as the "primary killer."
#space #earth
4 days ago
Lumson has purchased Lombardi Design and Manufacturing in the US, along with full ownership of Lombardi Design & MFG in Asia.
Financial terms of the deals remain undisclosed.
The deals form part of Lumson's wider international expansion plan and are intended to add to its industrial and technological capacity while extending its reach in primary packaging for the beauty and personal care sector.
With the two transactions, Lumson has a direct presence in Europe, North America and Asia.
The broader footprint will support work with international clients, help build industrial and commercial ties across markets, and open access to regions.
#financial #Europe
Financial terms of the deals remain undisclosed.
The deals form part of Lumson's wider international expansion plan and are intended to add to its industrial and technological capacity while extending its reach in primary packaging for the beauty and personal care sector.
With the two transactions, Lumson has a direct presence in Europe, North America and Asia.
The broader footprint will support work with international clients, help build industrial and commercial ties across markets, and open access to regions.
#financial #Europe
5 days ago
During the September 10 episode of Mad Money, a caller questioned whether recent vertical integration by industrial competitors and market selloffs warranted a lower valuation for Howmet Aerospace Inc.'s (NYSE:HWM) economic moat, or if demand remained strong enough to make the pullback an overreaction. Jim Cramer replied:
Now, look, I'll tell you, here's the problem… It's a fastener company, and it frankly is, most times, very commodity-oriented business, and it happens to sell at 44 times earnings, and we don't want to pay that for commodities even though the business is strong. I think people are saying, "Wait a second, that's too much to pay, and I'm going to wait till it goes lower." And if you look at the chart, it does seem like it is going lower.
Howmet Aerospace Inc. (NYSE:HWM) occupies a sole-source or primary-supplier position across critical narrowbody and widebody aircraft programs, providing single-crystal turbine blades, advanced structural castings, and **** anium fasteners. Approval and qualification requirements, manufacturing complexity, and a limited supplier base can make alternative sources difficult to establish quickly. That gives the company strong pricing power on both new plane parts and higher-margin replacement spares.
The structural advantages of Howmet Aerospace Inc.'s (NYSE:HWM) business model can be seen in its Q2 financial results. Revenue surged over 24% year-over-year (21% organically) to $2.55 billion, driven by a 28% jump in commercial aerospace revenue, a 38% expansion in industrial gas turbines, and an 11% gain in defense aerospace. The core Engine Products division recorded third-party sales of $1.37 billion, up 32% year-over-year, while segment adjusted EBITDA margins expanded by 470 basis points to 37.7%.
Despite its market positioning, Howmet Aerospace Inc. (NYSE:HWM) carries valuation risks that advise a cautious approach. Trading at elevated EV/EBITDA and forward P/E multiples relative to traditional industrial peers, the stock leaves little margin for operational missteps. Capital expenditures are projected to exceed $500 million in 2026 as the company builds out production capacity for next-generation engine components and gas turbines, reducing near-term free cash conversion flexibility.
#lower #ebitda
Now, look, I'll tell you, here's the problem… It's a fastener company, and it frankly is, most times, very commodity-oriented business, and it happens to sell at 44 times earnings, and we don't want to pay that for commodities even though the business is strong. I think people are saying, "Wait a second, that's too much to pay, and I'm going to wait till it goes lower." And if you look at the chart, it does seem like it is going lower.
Howmet Aerospace Inc. (NYSE:HWM) occupies a sole-source or primary-supplier position across critical narrowbody and widebody aircraft programs, providing single-crystal turbine blades, advanced structural castings, and **** anium fasteners. Approval and qualification requirements, manufacturing complexity, and a limited supplier base can make alternative sources difficult to establish quickly. That gives the company strong pricing power on both new plane parts and higher-margin replacement spares.
The structural advantages of Howmet Aerospace Inc.'s (NYSE:HWM) business model can be seen in its Q2 financial results. Revenue surged over 24% year-over-year (21% organically) to $2.55 billion, driven by a 28% jump in commercial aerospace revenue, a 38% expansion in industrial gas turbines, and an 11% gain in defense aerospace. The core Engine Products division recorded third-party sales of $1.37 billion, up 32% year-over-year, while segment adjusted EBITDA margins expanded by 470 basis points to 37.7%.
Despite its market positioning, Howmet Aerospace Inc. (NYSE:HWM) carries valuation risks that advise a cautious approach. Trading at elevated EV/EBITDA and forward P/E multiples relative to traditional industrial peers, the stock leaves little margin for operational missteps. Capital expenditures are projected to exceed $500 million in 2026 as the company builds out production capacity for next-generation engine components and gas turbines, reducing near-term free cash conversion flexibility.
#lower #ebitda
6 days ago
Kalib Perry is officially cleared to play for Louisville football (for now) and will be able to play in Saturday's game against No. 16 SMU.
On Monday, Sept. 14, a Jefferson County judge granted the linebacker's motion to join a lawsuit that granted several other athletes a temporary restraining order on the NCAA's stay request in the Wisne v. NCAA case. The stay request deemed those who entered college in 2022 ineligible of receiving a fifth year under the NCAA's new 5-for-5 ruling. Cardinals cornerback Jabari Mack is also part of the TRO and had two tackles and two pass breakups in the season opener.
Perry missed the first two games but is listed on the Cards' 2026 roster. He and Mack announced plans to come back to Louisville under the new 5-for-5 rule Aug. 15. They were active participants during the latter stages of fall camp until the NCAA's stay request was granted Aug. 21. Mack wasn't affected, having been part of the initial TRO, while Perry was deemed ineligible.
"Pretty much every day, we just call over compliance," Louisville head football coach Jeff Brohm said Aug. 21. "They tell us what we can do and not do, and we roll with it. … If your guys are here, you'd like them to be able to practice and play. So we're hopeful that can happen."
Perry was granted a motion to join the local lawsuit and apply the TRO to his eligibility on Sept. 3 but the NCAA filed an emergency appeal, which was denied, and a regular appeal after. In response to Perry's motion, the NCAA stated Thursday that Perry's inclusion "raises complex legal and factual issues that are not part of the primary dispute before the Court." It cited the football player having entered the NFL draft, though he went undrafted, and participated in NFL minicamps with the San Francisco 49ers and Tennessee ******* ans. On Aug. 27, the ACC released a statement that banned players that "previously declared for an NFL, NBA or WNBA Draft, and did not appropriately withdraw consistent with NCAA requirements to retain eligibility."
#mack
On Monday, Sept. 14, a Jefferson County judge granted the linebacker's motion to join a lawsuit that granted several other athletes a temporary restraining order on the NCAA's stay request in the Wisne v. NCAA case. The stay request deemed those who entered college in 2022 ineligible of receiving a fifth year under the NCAA's new 5-for-5 ruling. Cardinals cornerback Jabari Mack is also part of the TRO and had two tackles and two pass breakups in the season opener.
Perry missed the first two games but is listed on the Cards' 2026 roster. He and Mack announced plans to come back to Louisville under the new 5-for-5 rule Aug. 15. They were active participants during the latter stages of fall camp until the NCAA's stay request was granted Aug. 21. Mack wasn't affected, having been part of the initial TRO, while Perry was deemed ineligible.
"Pretty much every day, we just call over compliance," Louisville head football coach Jeff Brohm said Aug. 21. "They tell us what we can do and not do, and we roll with it. … If your guys are here, you'd like them to be able to practice and play. So we're hopeful that can happen."
Perry was granted a motion to join the local lawsuit and apply the TRO to his eligibility on Sept. 3 but the NCAA filed an emergency appeal, which was denied, and a regular appeal after. In response to Perry's motion, the NCAA stated Thursday that Perry's inclusion "raises complex legal and factual issues that are not part of the primary dispute before the Court." It cited the football player having entered the NFL draft, though he went undrafted, and participated in NFL minicamps with the San Francisco 49ers and Tennessee ******* ans. On Aug. 27, the ACC released a statement that banned players that "previously declared for an NFL, NBA or WNBA Draft, and did not appropriately withdraw consistent with NCAA requirements to retain eligibility."
#mack
6 days ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Gold can play a role in a diversified retirement portfolio, but it's generally better suited as a complement to stocks, bonds, and other investments than as a primary retirement ****** et.
Gold may help diversify a portfolio because it can perform differently from stocks and bonds under certain market conditions. But gold also has drawbacks, including lower long-term returns than stocks and, in the case of a gold IRA, potentially high storage and custodial fees.
How much gold belongs in your retirement portfolio depends on factors including your age, risk tolerance, time until retirement, and investment goals.
Gold can help diversify a retirement portfolio, but it shouldn't replace stocks, bonds, and other investments.
#Portfolio #including
Gold can play a role in a diversified retirement portfolio, but it's generally better suited as a complement to stocks, bonds, and other investments than as a primary retirement ****** et.
Gold may help diversify a portfolio because it can perform differently from stocks and bonds under certain market conditions. But gold also has drawbacks, including lower long-term returns than stocks and, in the case of a gold IRA, potentially high storage and custodial fees.
How much gold belongs in your retirement portfolio depends on factors including your age, risk tolerance, time until retirement, and investment goals.
Gold can help diversify a retirement portfolio, but it shouldn't replace stocks, bonds, and other investments.
#Portfolio #including
6 days ago
Energy Transfer LP (NYSE:ET) is set to move the primary listing of its common and Series I preferred units from the New York Stock Exchange to the Texas Stock Exchange in early October, making it the first major company to make such a switch from the NYSE to the newly established Dallas exchange. Reuters said the companies moving to TXSE, including Energy Transfer and related energy businesses, represent nearly $100 billion in combined market value, giving the fledgling exchange an important early credibility boost.
For Energy Transfer LP (NYSE:ET), however, the more important question is whether the move can eventually translate into better investor visibility or valuation rather than simply giving the company a stronger Texas identity. WSJ reported that Energy Transfer is worth roughly $75 billion and that Executive Chairman Kelcy Warren is a major backer of TXSE, owning about 30% of its parent company. That relationship makes the listing particularly significant, but it also means investors may scrutinize whether the decision creates a tangible benefit for Energy Transfer unitholders rather than primarily helping establish the new exchange.
The strongest bull argument is that Energy Transfer LP (NYSE:ET) is positioning itself ahead of a potentially important shift in the U.S. energy infrastructure market. TXSE is backed by major financial institutions including BlackRock, Citadel Securities, and Charles Schwab, and winning a roughly $75 billion company gives the exchange substantially more credibility with institutional investors. If TXSE attracts additional large energy companies, Energy Transfer could benefit from becoming one of the exchange's anchor names and gaining greater visibility among investors already focused on Texas-based energy infrastructure.
More importantly, the listing decision fits the underlying environment in which Energy Transfer LP (NYSE:ET) operates. Reuters has highlighted continued investment in U.S. gas-fired generation, LNG infrastructure, and pipeline networks as electricity demand rises and countries seek reliable energy supplies. The U.S. is also building substantial additional LNG export capacity. That matters because Energy Transfer's extensive midstream network can benefit from higher volumes of natural gas, crude oil, and NGLs without taking the same direct commodity-price exposure as upstream producers. If rising power demand from data centers and continued LNG development drive greater demand for U.S. gas transportation, Energy Transfer could see expanding opportunities to place additional infrastructure into service and lock in long-duration cash flows.
#transfer #company #infrastructure #listing
For Energy Transfer LP (NYSE:ET), however, the more important question is whether the move can eventually translate into better investor visibility or valuation rather than simply giving the company a stronger Texas identity. WSJ reported that Energy Transfer is worth roughly $75 billion and that Executive Chairman Kelcy Warren is a major backer of TXSE, owning about 30% of its parent company. That relationship makes the listing particularly significant, but it also means investors may scrutinize whether the decision creates a tangible benefit for Energy Transfer unitholders rather than primarily helping establish the new exchange.
The strongest bull argument is that Energy Transfer LP (NYSE:ET) is positioning itself ahead of a potentially important shift in the U.S. energy infrastructure market. TXSE is backed by major financial institutions including BlackRock, Citadel Securities, and Charles Schwab, and winning a roughly $75 billion company gives the exchange substantially more credibility with institutional investors. If TXSE attracts additional large energy companies, Energy Transfer could benefit from becoming one of the exchange's anchor names and gaining greater visibility among investors already focused on Texas-based energy infrastructure.
More importantly, the listing decision fits the underlying environment in which Energy Transfer LP (NYSE:ET) operates. Reuters has highlighted continued investment in U.S. gas-fired generation, LNG infrastructure, and pipeline networks as electricity demand rises and countries seek reliable energy supplies. The U.S. is also building substantial additional LNG export capacity. That matters because Energy Transfer's extensive midstream network can benefit from higher volumes of natural gas, crude oil, and NGLs without taking the same direct commodity-price exposure as upstream producers. If rising power demand from data centers and continued LNG development drive greater demand for U.S. gas transportation, Energy Transfer could see expanding opportunities to place additional infrastructure into service and lock in long-duration cash flows.
#transfer #company #infrastructure #listing
6 days ago
Eli Willits has made his primary goal crystal clear ever since he joined the Nationals organization. He wants to be a big leaguer by the time he is 20 years old. For most players, that is a pipe dream. However, Eli Willits is not most players and he made that very obvious this season.
The 18 year old just finished his first professional season in style. Willits got promoted to Double-A for the last week of the season. While he only got to play three games, the last one was legendary. Willits had a four hit game which included his first AA home run and two stolen bases. It was an amazing final act to a wonderful season.
With Willits finishing the season in AA, he is putting himself in position to make a debut late in 2027. Despite being such a young player, Willits is remarkably polished. This comes from being the son of a big leaguer and being obsessed with the game ever since he could walk.
When I talked to Willits earlier this season, it was very clear that three things truly mattered to him. Eli Willits is all about family, faith and baseball. You will be hard pressed to find a more business-like 18 year old out there. As Willits put it, he grew up in an MLB clubhouse and it is easy to see that.
That baseball IQ manifests itself on the field. When I watched Willits for the first time in Low-A, the thing that stuck out to me most was how natural he looked. Willits looked like a big league caliber defender at shortstop already. While many young shortstops, even the defensively gifted ones make a lot of errors, Willits is already so secure. He only made 8 errors all season as an 18 year old.
#season #year
The 18 year old just finished his first professional season in style. Willits got promoted to Double-A for the last week of the season. While he only got to play three games, the last one was legendary. Willits had a four hit game which included his first AA home run and two stolen bases. It was an amazing final act to a wonderful season.
With Willits finishing the season in AA, he is putting himself in position to make a debut late in 2027. Despite being such a young player, Willits is remarkably polished. This comes from being the son of a big leaguer and being obsessed with the game ever since he could walk.
When I talked to Willits earlier this season, it was very clear that three things truly mattered to him. Eli Willits is all about family, faith and baseball. You will be hard pressed to find a more business-like 18 year old out there. As Willits put it, he grew up in an MLB clubhouse and it is easy to see that.
That baseball IQ manifests itself on the field. When I watched Willits for the first time in Low-A, the thing that stuck out to me most was how natural he looked. Willits looked like a big league caliber defender at shortstop already. While many young shortstops, even the defensively gifted ones make a lot of errors, Willits is already so secure. He only made 8 errors all season as an 18 year old.
#season #year
6 days ago
NEW YORK — Forget the Honey Deuces and the celebrities-in-the-audience shots. The finest element of the U.S. Open — the Grand Slam held in the largest tennis stadium in the world — will always be the tennis itself. The trick, in 2026 and beyond, is how to get audiences to actually care about, you know, that tennis.
Ben Shelton and Alexander Zverev did their very best on Sunday, bringing both narrative and firepower to the four-set men's final. Yes, the influencers were posing at every aisle on every changeover, and more than a few fans appeared unclear on the basic concept of "sit your ******* down while the point is going on." But when Shelton and Zverev locked in, unleashing serves that nearly hit 150 mph or lashing shots that skipped a fingernail's width in bounds, the crowd was right there with them, rising and falling, a living thing that pulsed with energy unlike any other stadium in tennis.
Less than 24 hours earlier on the same court, Elena Rybakina finished off Aryna Sabalenka in a three-set triumph of resolve and willpower over emotion and firepower. Sabalenka, who had won the previous two Opens, entered as the crowd favorite. But the fans in the stands at Arthur Ashe love hard-fought on-court battles as much as they love the endless scroll of celebrity cameos on the video boards. So after a couple dozen Hollywood and music stars took their turns to varying volumes of applause, the crowd focused in on the match. Sabalenka drew motivational cheers, and then, once the result was clear, Rybakina inspired celebratory ones.
The two matches ended this year's U.S. Open on a triumphant note. At last, the tennis tournament centered on actual tennis, not ticket prices or runway-style entrances to Arthur Ashe Stadium or hundred-dollar chicken nuggets. (Yes, I admit it, I was part of the problem with that last one.)
The influencers' presence dominated the early coverage of the U.S. Open, in large part because they did their job of drawing attention to themselves. But by the time the tournament reached its final crescendo, the influencers had moved on. Two hours before the men's final, the cheapest tickets to get in the stadium could be had for less than $400, suggesting that tennis for tennis' sake isn't the primary motivator for many attending the U.S. Open.
#crowd #shelton
Ben Shelton and Alexander Zverev did their very best on Sunday, bringing both narrative and firepower to the four-set men's final. Yes, the influencers were posing at every aisle on every changeover, and more than a few fans appeared unclear on the basic concept of "sit your ******* down while the point is going on." But when Shelton and Zverev locked in, unleashing serves that nearly hit 150 mph or lashing shots that skipped a fingernail's width in bounds, the crowd was right there with them, rising and falling, a living thing that pulsed with energy unlike any other stadium in tennis.
Less than 24 hours earlier on the same court, Elena Rybakina finished off Aryna Sabalenka in a three-set triumph of resolve and willpower over emotion and firepower. Sabalenka, who had won the previous two Opens, entered as the crowd favorite. But the fans in the stands at Arthur Ashe love hard-fought on-court battles as much as they love the endless scroll of celebrity cameos on the video boards. So after a couple dozen Hollywood and music stars took their turns to varying volumes of applause, the crowd focused in on the match. Sabalenka drew motivational cheers, and then, once the result was clear, Rybakina inspired celebratory ones.
The two matches ended this year's U.S. Open on a triumphant note. At last, the tennis tournament centered on actual tennis, not ticket prices or runway-style entrances to Arthur Ashe Stadium or hundred-dollar chicken nuggets. (Yes, I admit it, I was part of the problem with that last one.)
The influencers' presence dominated the early coverage of the U.S. Open, in large part because they did their job of drawing attention to themselves. But by the time the tournament reached its final crescendo, the influencers had moved on. Two hours before the men's final, the cheapest tickets to get in the stadium could be had for less than $400, suggesting that tennis for tennis' sake isn't the primary motivator for many attending the U.S. Open.
#crowd #shelton
